NCT07449910

Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial

Safety and Efficacy of Baricitinib Combined With Acute Large Vessel Occlusion Recanalization : A Multicenter, Randomized Controlled Clinical Trial

• Status: Not Yet Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 750 (estimated)
• Sponsor: The First Affiliated Hospital of University of Science and Technology of China · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this study is to evaluate the efficacy and safety of Baricitinib combined with endovascular therapy in patients with acute anterior circulation large vessel occlusion, to address futile recanalization with priority, and to elucidating the mechanism of JAK/STAT pathway inhibition on neuroprotection and inflammatory regulation.

Conditions

• Acute Ichemic Stroke
• Anterior Cerebral Artery Stroke
• Baricitinib

Interventions

Type	Name	Description
DRUG	2mg Baricitinib	One 2mg Baricitinib tablet and one 2mg placebo tablet are given three times a day, last for 5±2 days.
DRUG	4mg Baricitinib	Two 2mg Baricitinib tablets are given three times a day, last for 5±2 days.
DRUG	Placebo	Two 2mg placebo tablets are given three times a day, last for 5±2 days.
OTHER	Guideline-based therapy	Guideline-based therapy including EVT treatment is determined by the physician.

Timeline

• Start date: 2026-03-17
• Primary completion: 2027-08-17
• Completion: 2028-01-31
• First posted: 2026-03-04
• Last updated: 2026-03-04

Locations

1 site across 1 country: China